SCHEMBL4298265

SCHEMBL4298265

Cc1cccc(OC2CCCN(C(=O)c3cccc(N4CCCNCC4)n3)C2)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 2/20 0.42
HCRTR2 O43614 2/20 0.42
PRKCA P17252 2/20 0.42
PRKCQ Q04759 2/20 0.42
PRKCD Q05655 2/20 0.42
HRH3 Q9Y5N1 2/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
DGAT2 Q96PD7 1/20 0.39
ACACB O00763 4/20 0.38
SPR P35270 1/20 0.38
PIM1 P11309 2/20 0.37
PIM3 Q86V86 2/20 0.37
PIM2 Q9P1W9 2/20 0.37
MGLL Q99685 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4305001 1.00 HCRTR1 (0.42) HCRTR1HCRTR2PRKCAPRKCQPRKCD
SCHEMBL4298258 1.00 HCRTR1 (0.42) HCRTR1HCRTR2PRKCAPRKCQPRKCD
SCHEMBL4296322 0.96 PRKCA (0.43) HCRTR1HCRTR2PRKCAPRKCQPRKCD
SCHEMBL4296319 0.96 PRKCA (0.43) HCRTR1HCRTR2PRKCAPRKCQPRKCD
SCHEMBL4299128 0.91 PRKCA (0.44) HCRTR1HCRTR2PRKCAPRKCQPRKCD
SCHEMBL4299124 0.91 PRKCA (0.44) HCRTR1HCRTR2PRKCAPRKCQPRKCD
SCHEMBL4303632 0.91 PRKCA (0.44) HCRTR1HCRTR2PRKCAPRKCQPRKCD
SCHEMBL4298083 0.90 HRH3 (0.50) HCRTR1HCRTR2PRKCAPRKCQPRKCD
SCHEMBL4298087 0.90 HRH3 (0.50) HCRTR1HCRTR2PRKCAPRKCQPRKCD
SCHEMBL4301609 0.90 HRH3 (0.50) HCRTR1HCRTR2PRKCAPRKCQPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders HTR6, HTR5A, TPH1 HCRTR1 106/4885HCRTR2 203/4885PRKCA 3735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.